MT-501 / Mirador Therapeutics - LARVOL DELTA

ASCEND-IBD: A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Mirador Therapeutics, Inc. | N=90 ➔ 140 | Trial completion date: May 2027 ➔ Feb 2028 | Trial primary completion date: Jul 2026 ➔ Apr 2027

Enrollment change • Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

MT-100-201: A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease (clinicaltrialsregister.eu) - P1/2 | N=54 | Not yet recruiting | Sponsor: Mirador Therapeutics Inc.

New P1/2 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A First-in-Human Single and Multiple Ascending Dose Study of MT-501 (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Mirador Therapeutics, Inc. | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ May 2025 | Trial primary completion date: Jan 2026 ➔ May 2025

First-in-human • Trial completion • Trial completion date • Trial primary completion date

ASCEND-IBD: A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Mirador Therapeutics, Inc.

New P2 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A First-in-Human Single and Multiple Ascending Dose Study of MT-501 (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Mirador Therapeutics, Inc. | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date